Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: Identification of children at high risk of morbidity and mortality from sepsis

Bone Marrow Transplantation

Volumn 31, Issue 12, 2003, Pages 1137-1142

  Sauer, M ^a   Tiede, K ^b   Fuchs, D ^b   Gruhn, B ^b   Berger, D ^c   Zintl, F ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

C reactive protein; Children; Endotoxin; Infection; Neutropenia; Procalcitonin; Sepsis; Shock; Survival

Indexed keywords

AMPHOTERICIN B; BUSULFAN; C REACTIVE PROTEIN; CEFAZOLIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOTOXIN; FLUCONAZOLE; MELPHALAN; METHOTREXATE; NYSTATIN; PREDNISONE; PROCALCITONIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTOXIN DETECTION; FEMALE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; ENDOTOXINS; FEMALE; GERMANY; HUMANS; INFANT; MALE; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SEPSIS; SHOCK, SEPTIC;

EID: 0038780025     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704045     Document Type: Article

References (30)

1. Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-123.
2. Linde-Zwirble WT, Angus DC, Carcillo JA et al. Age specific incidence and outcome of sepsis in the US. Crit Care Med 1999; 27 (Suppl.) A33.
3. Wald A, Leisenring W, Vanburik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
4. Williamson EC, Millar MR, Steward CG et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-568.
5. Knaus WA, Harrell Jr, FE, LaBrecque JF et al. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24: 46-56.
6. Staudinger T, Presterl E, Graninger W et al. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Inten Care Med 1996; 22: 888-893.
7. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin-a new indicator of the systemic response to severe infections. Infection 1997; 25: 329-334.
8. Oberhoffer M, Karzai W, Meier-Hellmann A et al. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med 1999; 27(9): 1814-1818.
9. Chiesa C, Pacifico L, Mancuso G, Panero A. Procalcitonin in pediatrics: overview and challenge. Infection 1998; 26: 236-241.
10. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
11. de Werra I, Jaccard C, Corradin SB et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25: 607-613.
12. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997; 16: 735-746; [quiz 746-747].
13. van Deventer SJ, Buller HR, ten Cate JW et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.
14. Storb R, Leisenring W, Anasetti C et al. Methotrexate and cyclosporine for graft-vs-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997; 3: 194-201.
15. Meisner M, Brunkhorst FM, Reith HB et al. Clinical experiences with a new semi-quantitative solid phase immunoassay for rapid measurement of procalcitonin. Clin Chem Lab Med 2000; 38: 989-995.
16. Bates DW, Parsonnet J, Ketchum PA et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group. Clin Infect Dis 1998; 27: 582-591.
17. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
18. Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interieukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
19. van Dissel JT, van Langevelde P, Westendorp RG et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351: 950-953.
20. Bayston KF, Cohen J. Bacterial endotoxin and current concepts in the diagnosis and treatment of endotoxaemia. J Med Microbiol 1990; 31: 73-83.
21. Danner RL, Elin RJ, Hosseini JM et al. Endotoxemia in human septic shock. Chest 1991; 99: 169-175.
22. Anonymous. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infectious Dis 1991; 163: 951-958.
23. Sturk A, van Deventer SJ, Wortel CH et al. Detection and clinical relevance of human endotoxemia. Z Medi Laboratoriumsdiagnostik 1990; 31: 147-158.
24. Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-1608.
25. Kirsch EA, Giroir BP. Improving the outcome of septic shock in children. Curr Opin Infect Dis 2000; 13: 253-258.
26. Gendrel D, Raymond J, Coste J et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs viral infections. Pediatr Infect Dis J 1999; 18: 875-881.
27. Engel A, Mack E, Kern P, Kern WV. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 1998; 26: 213-221.
28. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
29. Castellanos-Ortega A, Delgado-Rodriguez M. Comparison of the performance of two general and three specific scoring systems for meningococcal septic shock in children. Crit Care Med 2000; 28: 2967-2973.
30. Goldhill DR, Sumner A. APACHE II, data accuracy and outcome prediction. Anaesthesia 1998; 53: 937-943.